A Phase II Study of AK104 Plus Lenvatinib and TACE in HCC
Clinical trial NCT05319431 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05319431
- Sponsor
- Akeso
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2022-06-28
- Primary completion
- 2023-08-15
- Enrollment
- 60
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.